medRxiv preprint doi: https://doi.org/10.1101/2023.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Title: Cervicovaginal and anal self-sampling for HPV testing in a transgender and gender diverse population assigned female at birth: comfort, difficulty, and willingness to use

Authors: Erin F Welsh¹, Emily C. Andrus¹, Claire B. Sandler¹, Molly B. Moravek², Daphna Stroumsa², Shanna K. Kattari^{3,4}, Heather M. Walline⁵, Christine M. Goudsmit⁵, Andrew F. Brouwer^{1,*}

Affiliations:

- 1. Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States
- 2. Reproductive Endocrinology Clinic, Center for Reproductive Medicine, University of Michigan, Ann Arbor, MI, United States
- 3. School of Social Work, University of Michigan, Ann Arbor, MI, United States
- 4. Department of Women's and Gender Studies, University of Michigan, Ann Arbor, MI, United States
- 5. Department of Otolaryngology, University of Michigan, Ann Arbor, MI, United States

Corresponding author^{*}: email: brouweaf@umich.edu; mail: Department of Epidemiology, 1415 Washington Heights, Ann Arbor, MI, 48109, United States

1	Abstract
2	
3	Background: Transgender and gender diverse (TGD) people assigned female at birth (AFAB)
4	face numerous barriers to preventive care, including for HPV and cervical cancer screening.
5	Self-sampling options may expand access to HPV testing for TGD people AFAB.
6	
7	Methods: We recruited TGD individuals AFAB to collect cervicovaginal and anal specimens at-
8 9 (home using self-sampling for HPV testing, and individuals reported their perceptions of self- dRxiv preprint doi: https://doi.org/10.1101/2023.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this preprint version posted August 16, 2023. The copyright holder for this posted August 16, 2023. The copyright holder for this posted August 16, 2023. The copyright holder for tholder for t
10	use, ease of use, and willingness to use self-sampling were estimated using robust Poisson
11	regression.
12	
13	Results: The majority of the 101 participants who completed the study reported that the
14	cervicovaginal self-swab was not uncomfortable (68.3%) and not difficult to use (86.1%), and
15	nearly all (96.0%) were willing to use the swab in the future. Fewer participants found the anal
16	swab to not be uncomfortable (47.5%), but most participants still found the anal swab to not be
17	difficult to use (70.2%) and were willing to use the swab in the future (89.1%). Participants were
18	more willing to use either swab if they had not seen a medical professional in the past year.
19	About 70% of participants who reported negative experiences with either self-swab were still
20	willing to use that swab in the future.
21	
22	Conclusions: TGD AFAB individuals were willing to use and preferred self-sampling methods
23	for cervicovaginal and anal HPV testing. Developing clinically approved self-sampling options
24	for cancer screening could expand access to HPV screening for TGD AFAB populations.
25	
26	Keywords: HPV, transgender, gender diverse, cervicovaginal, anal, oral, self-sampling
27	
28	

29 Introduction

30 The human papillomavirus (HPV) is the most common STI among sexually active people, with

most adults contracting at least one HPV strain during their lifetime.¹ HPV infections are typically 31

- 32 asymptomatic and clear in 1-2 years, but they have the potential to contribute to future health
- 33 issues such as genital warts and cancer of the cervix, anal canal, and oropharynx.

Approximately 22,000 instances of HPV-attributable cancer are diagnosed annually in the US 34

35 among those assigned female at birth (AFAB), including 11,100 cases of cervical cancer, 4,700

cases of anal cancer, and 2,300 cases of oropharyngeal cancer each year.¹ While the risk of 36 medRxiv preprint doi: https://doi.org/10.1101/2023.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint 37 (while was non-scientific and by not single protection and an ingle scalar and the protection of the second science and the secon

not mitigate risk completely. Additionally, while HPV vaccines are highly effective in unexposed 38

individuals, uptake has lagged, and the vaccines are less effective in individuals who have been 39

previously infected.² Accordingly, cervical cancer screening remains an important preventive 40 measure.

41

42

Per the US Preventive Services Task Force (USPSTF), current cervical cancer screening 43 guidelines recommend that (cisgender) women aged 21-29 years should undergo a Pap smear 44 every three years. For women aged 30-65 years, the USPSTF suggests either continuing with a 45 46 Pap smear every three years, or combining it with high-risk HPV testing, which should be conducted every five years.³ Preventive cancer screening relies on regular engagement with 47 health care practitioners and facilities. Transgender and gender diverse (TGD) individuals AFAB 48 49 face many barriers to receiving preventive care, including cancer screening. (In this study, TGD 50 includes transgender, nonbinary/gender diverse, both, or, in the case of AFAB individuals identifying as male, neither identities). TGD individuals are an especially vulnerable population, 51 52 facing numerous barriers to accessing healthcare services, including discrimination, lack of provider knowledge and training, insurance exclusions, and financial barriers.^{4,5} Many TGD 53 individuals report delaying medical care due to fear of discrimination, providers lacking trans-54 specific medical care knowledge, dysphoria, and discomfort.^{4,5} Delaying medical care places 55 additional health risks on an already vulnerable population. Hysterectomy is rare among TGD 56 AFAB individuals⁶, so cervical screening remains an important part of preventive care for this 57 population. HPV testing and cervical cancer screening recommendations do not distinguish 58 between cisgender (i.e., non-TGD) women and TGD individuals, despite evidence that TGD 59 patients are substantially more likely to have inconclusive test results.^{7,8} In addition, healthcare 60 providers may recommend anal cancer screening using anal Pap smears or HPV testing in 61 transmasculine individuals who engage in receptive anal sex.9 62 63

64 There is limited research on the prevalence of HPV and HPV-related cancers in transmasculine individuals compared to the cisgender population.¹⁰ While TGD individuals AFAB are often 65 66 considered by providers and patients to be at lower risk of HPV infection because of supposedly 67 lower rates of intercourse with partners with a penis, some studies suggest that transmasculine 68 individuals may have a higher risk of cervical cancer and other HPV-related cancers than 69 cisgender women due to retention of the uterine cervix, increased sexual activity, and a lack of routine cancer screenings.^{11,12} At-home HPV testing has the potential to improve the healthcare 70 experience of TGD individuals by providing a more private and convenient testing option and 71 ultimately reduce healthcare disparities.^{13,14} This study aims to bridge the gap in barriers to 72 73 healthcare and HPV screening for the TGD population by assessing the feasibility of

- 74 administering self-collected cervicovaginal and anal swabs for HPV testing at home, as well as
- 75 swab comfort, ease-of-use, and acceptability.
- 76

77 Materials and Methods

- 78 Study design and population
- 79 This observational study enrolled participants in 2020–21 and investigated prevalence of
- 80 cervicovaginal, oral, and anal HPV among TGD people AFAB using at-home self-sampling and
- 81 to assess comfort, ease-of-use, and preference for at-home cervicovaginal and anal HPV medRxiv preprint doi: https://doi.org/10.1101/2023.08.15.23294132: this version posted August 16.2023. The copyright holder for this pre-
- medRxiv preprint doi: https://doi.org/10.1101/2023.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint 82 (vtestings not bistionallysis focuses on participant shoes and version solutions and version solutions and version and the atthiom erpetuity. It is made available under a CC-BY-NC 4.0 International license.
- 83 cervicovaginal and anal specimen sampling process. The University of Michigan Institutional
- 84 Review Board and the Rogel Cancer Center Protocol Review Committee approved consent
- 85 documents and study protocol (HUM00166980). Ten TGD community members reviewed the
- 86 study protocol, surveys, and sample collection instructions; each person was compensated with
- 87 a \$100 gift card for their time.
- 88
- 89 Participants were recruited through the Michigan Medicine Comprehensive Gender Services
- 90 Program, the Michigan Medicine research study recruitment website, social media posts,
- 91 outreach to LGBT+ organizations, and word of mouth referrals. To qualify for the study,
- 92 participants had to meet the following inclusion criteria: (1) be able and willing to provide
- consent, (2) be between the ages of 21–65 years of age, (3) be assigned female at birth, (4)
- 94 identify as male, masculine, nonbinary, or another TGD identity, and (5) live in Michigan, Illinois,
- 95 Indiana, Ohio, or Wisconsin. Individuals were excluded from participating if they: (1) had their
- 96 cervix removed, or (2) self-reported being pregnant. Samples could not be collected if
- 97 participants were menstruating. Participants gave written, informed consent virtually, using the
- 98 SignNow platform. Participants were compensated with a \$50 gift card for full study
- 99 participation.
- 100
- 101 Procedures
- 102 Sample self-collection. Individuals who consented to participate were mailed a study test kit that
- included materials and instructions for the collection of cervicovaginal, oral, and anal
- biospecimens. Participants were asked to provide an oral rinse sample using Scope brand
- 105 mouthwash (Proctor & Gamble), a cervicovaginal sample using an Evelyn Brush (Rovers
- 106 Medical Devices), and an anal sample using a Dacron flocked swab (Puritan Medical
- 107 Products).^{16,17} The Evalyn Brush is a cervicovaginal sampling device designed to collect cells
- 108 near the cervix. The protocol for anal swab sampling was adapted from previously published
- 109 protocols.^{18,19} More details on sample collection and analysis are provided in McIntosh et al.¹⁵
- 110
- 111 Questionnaire. Following sample collection, participants were asked to complete two
- 112 questionnaires. First, participants completed a questionnaire adapted from the validated
- instrument developed for the Michigan HPV and Oropharyngeal Cancer Study, consisting of
- 114 questions relating to demographic information, including age, race/ethnicity, and socioeconomic
- status; behavior, including alcohol, tobacco, and other drug use; and sexual practices, sexual
- history, and sexual health care (including HPV vaccination status), testosterone status, general
- 117 health, and history of STIs.¹⁹ Secondly, to assess participants' individual at-home self-sampling
- experiences, participants answered a questionnaire was adapted from a previously developed

- instrument, consisting of the comfort, ease-of-use, and preference for the cerivcovaginal and
- 120 anal self-collection procedures.²⁰ Oral sampling for HPV was not similarly assessed as it uses a
- 121 non-invasive sampling method (oral rinse).
- 122

123 Statistical analysis

124 This study assessed three primary outcomes: perception of self-sampling swab comfortability,

125 perception of self-sampling difficulty, and willingness to use the self-sampling method for future

HPV testing. Comfort and ease-of-use were asked on a Likert scale (1-5) but analyzed as binary
 medRxiv preprint doi: https://doi.org/10.1101/2023.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint
 (voiutic once with fixed bace 4-6 vindicating the/iswab was as proved for this leader difficults to use provide a state of the context of the context

- ratios and 95% confidence intervals were estimated using Poisson regression with robust error
 variance. All analyses were conducted using SAS 9.4. Statistical significance is reported at level
- 131 2 = 0.05.
- 132

133 Results

134 Sample characteristics

135 We enrolled 137 TGD participants, and 101 participants completed both the HPV self-swab

- 136 collections and questionnaires. The mean age of the cohort was 28.6 years, with two-thirds of
- the population falling into the 21–29-year age group (Table 1). There was an even distribution of
- 138 gender identity between those identifying as nonbinary, genderfluid, agender, or another gender
- diverse identity (48.0%) and as transgender male, transmasculine, male, or another transgender
- identity (49.0%). Most of the participants identified their sexual orientation as either bisexual,
- pansexual, or omnisexual (43.1%) or queer (36.3%). Most participants reported ever delaying
- 142 medical care due to concerns relating to their gender identity (82.2%), such as expected lack of
- 143 provider knowledge on transgender care, fear of discrimination, and dysphoria (Table 2). Three-
- 144 quarters of participants reported having transitioned or be in the process of transitioning from
- their gender assigned at birth, and, of those individuals, 89.3% were currently on testosterone
- 146 hormone therapy for masculinization. A small percentage reported a previous history of
- 147 pregnancy (13.9%). The average BMI was 29.3, with there being an increasing distribution
- among individuals who are classified as normal weight (26.6%), overweight (33.0%), and obese
- 149 (36.2%). Most of the population had prior experience receiving a cervical Pap test (78.2%), but
- 150 few (5.9%) reported prior experience of an anal HPV test. Over half of the population reported
- 151 receiving at least one dose of the HPV vaccine.
- 152

153 Perceptions of cervicovaginal self-swab collection

154 Overall, perceptions of the cervicovaginal self-swab collection for HPV were positive (Table 3).

- 155 A large proportion of the subjects reported that using the cervicovaginal swab was not
- uncomfortable (68.3%), as well as not difficult to use (86.1%). Participants with a history of
- 157 pregnancy were more likely to report that the swab was not uncomfortable (PR 1.31; 95% CI
- 158 1.91, 1.70), and those who reported delayed medical care due to their gender identity were less
- 159 likely to report the swab was not uncomfortable compared to those who never delayed medical
- 160 care (PR 0.72; 95% CI 0.56, 0.92). None of the demographic or health-related variables were
- significantly associated with an individual's perception that the cervicovaginal swab was easy to
- use. Perceptions of the swab being comfortable and being easy to use were strongly correlated.
- 163

- 164 Nearly all participants expressed that they would be willing to use the cervicovaginal self-swab
- in the future for HPV and cervical cancer screening (96.0%). There were few significant
- 166 differences in willingness to use the self-swab by any of the demographic, sexual history,
- 167 medical history, or transition history characteristics, except that those who had not seen a
- 168 medical professional within the past year were more willing to use the cervicovaginal self-swab
- than those that had (PR 1.04; 95% CI 1.00, 1.09). Willingness to use the swab was lower
- among those who found the swab to be uncomfortable (PR 0.71; 95% CI 0.51, 0.99). There was
- 171 an overall preference for at-home self-swab collection for cervicovaginal HPV testing, with medRxiv preprint doi: https://doi.org/10.1101/203.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint 172 (*68:8% preferring dat home testing even ally idem pares to the 9% preferring in colliplex dellection in peraetuity. It is made available under a CC-BY-NC 4.0 International license.
- 173 physician, 11.9% preferring a pap test in the clinic, and 12.9% with no preference.
- 174
- 175 Perceptions of anal self-swab collection
- Perceptions of the anal self-swab for HPV testing were less positive than those about the 176 cervicovaginal self-swab (Table 4). Only half (47.5%) of participants reported the anal swab to 177 178 not be uncomfortable, and though most still perceived the anal swab to not be difficult to use 179 (70.2%). Participants were more likely to find the swab to be uncomfortable if they had public 180 health insurance compared to private insurance (PR 0.51; 95% CI 0.28, 0.92), but were more 181 likely to find the swab to not be uncomfortable if they had not seen a medical professional within 182 the past year compared to those who had (PR 1.66; 95% CI 1.05, 2.63), had delayed medical care due to the provider lacking trans-specific knowledge compared to those that had not (PR 183 184 3.00; 95% CI 1.07, 8.43), or delayed medical care due to fear of discrimination compared to 185 those that had not (PR 2.81; 95% CI 1.09, 7.23). Participants were more likely to find the swab 186 to be difficult to use if they were 30–39 years old compared to 21–29 years old (PR 0.66; 95% 187 CI 0.45, 0.95), but more likely to not find the swab difficult to use if they were Asian compared to 188 White (PR 1.43; 95% CI 1.24, 1.65), lived in a rural area compared to a suburban area (PR 189 1.53; 95% CI 1.25, 1.88), delayed medical care because the medical professional lacked 190 knowledge on trans-specific healthcare compared to those that did not (PR 2.00; 95% CI 1.26, 191 1.67). Comfort and ease-of-use of the swab were again strongly correlated.
- 192

193 Overall, most participants reported they would be willing to use the anal self-swab for future anal HPV testing (89.1%). Participants were more likely to be willing to use the anal swab if they 194 195 were older (40-59 vs 21-29 years old: PR 1.12; 95% Cl 1.03, 1.22), resided in a rural area 196 compared to a suburban area (PR 1.19; 95% CI 1.06, 1.35), if they had not visited a medical 197 professional in the past year (PR 1.13; 95% CI 1.05, 1.22), and they had transitioned but were not currently using hormones for masculinization. Both finding the anal swab uncomfortable (PR 198 199 0.72; 95% CI 0.57, 0.91) and finding the anal swab difficult (PR 0.79; 95% CI 0.69, 0.91) were 200 associated with decreased willingness to use the swab in the future. There was an overall 201 preference for at-home self-swab for anal HPV testing, with 66.3% of the population preferring 202 at home HPV testing, compared to 12.9% preferring an HPV test performed in clinic and 203 collected by a medical professional, 7.9% preferring an anal Pap test, and 12.9% having no 204 preference.

205

- 206 Self-reported qualitative reasons for cerivcovaginal and anal swab difficulty
- 207 Fourteen participants (14%) reported a difficult and/or distressing experience with using the
- 208 cervicovaginal swab, but ten (71%) of whom reported they would still be willing to use the

- 209 cervicovaginal self-swab for HPV testing in the future. Among the four participants who gave
- 210 reasons for their negative experience using the cervicovaginal swab, three cited pain or
- 211 discomfort when using the swab, and two cited emotional distress or dysphoria. Discomfort and
- 212 emotional distress were known potential risks disclosed in the consent form, and participants
- 213 were given contact information for TGD-supportive resources. Thirty participants (30%) reported
- a difficult or distressing experience with using the anal swab, but twenty-one (70%) reported
- they would still be willing to use the anal self-swab for HPV testing in the future. Seventeen

216 participants described their negative experiences. Nine participants described difficulty with medRxiv preprint doi: https://doi.org/10.1101/2023.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint 217 (vinse wing the swabbinte their and seine software to support the size of the siz

- and needing partner assistance. Three participants described the experience as awkward or
- 219 unfamiliar but not necessarily painful. Two reported emotional distress but noted that they
- appreciated the ability to do the test in the comfort of their own homes.
- 221

222 Discussion

223 Our analysis of the perceptions of the cervicovaginal and anal self-swab collection in a 224 Midwestern TGD population indicated an overall broad acceptance of self-swab collection 225 methods for HPV testing. For both the cervicovaginal and anal swabs, most participants 226 indicated they would be willing to use these self-collection methods again in the future for HPV 227 testing and cancer screening (96% for cervicovaginal swab, 89% for anal swab). We also found 228 that despite difficulty or discomfort, participants reported an overall willingness to use the swabs 229 in the future (71% and 70% of those reporting difficulty/discomfort, respectively). The preference 230 for at-home self-swab collection for HPV testing also suggests that self-collection may be a 231 more acceptable and accessible option for TGD individuals, who may experience discomfort or 232 discrimination in healthcare settings. Most demographic characteristics were not significantly 233 associated with participants' willingness to use the cervicovaginal self-swab for future 234 cervicovaginal HPV testing. However, older and rural participants were more willing to use the

- anal self-swab.
- 236

237 While participants overall reported a positive experience with cervicovaginal swab self-sampling, 238 a small fraction did express some discomfort with using the swab or reported that the process 239 generated feelings of dysphoria and emotional distress. Several participants reported that 240 although the act of cervicovaginal self-sampling was not necessarily inherently unpleasant or 241 painful, it was awkward and outside of their usual experiences. Increased familiarity and 242 normalization of the procedure may improve overall acceptability and comfort. Participants 243 reported mixed experiences with the anal self-swab in particular. Some individuals encountered 244 difficulty with insertion, with a few noting challenges in maneuvering the swab due to their body 245 size and shape or lack of flexibility. Others required assistance from their partner to properly use 246 the swab. These experiences suggest that alternative instructions or guidance for diverse body 247 types and positions may be beneficial for future self-sampling protocols. Additionally, anxiety 248 emerged as a common theme among participants for both the cervicovaginal and anal swabs. 249 While some individuals expressed a sense of unease or emotional distress during the self-250 sampling processes, they also noted a preference for experiencing these emotions in the 251 privacy of their homes rather than in a clinical setting. This result highlights the potential benefit 252 of self-sampling in mitigating the anxiety that some individuals may experience during in-person 253 screening procedures.

254

255 The findings of our study align with previous research on HPV testing within the TGD population, which has highlighted the unique challenges and barriers faced by this population.^{5,9} 256 257 Most participants in our study reported delaying medical care due to concerns related to their 258 gender identity. This result emphasizes the importance of addressing TGD-specific barriers to healthcare by improving provider knowledge in TGD healthcare and creating more inclusive and 259 comfortable environments.²² The acceptance and willingness to use self-collection methods 260 aligns with previous research suggesting that self-sampling for HPV testing is a promising 261 medRxiv preprint doi: https://doi.org/10.1101/2023.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint (valternative for if @ Dyindividuals is who analyte where where discomforts on anxiety disting fractitional erpetuity. It is made available under a CC-BY-NC 4.0 International license. Clinician-collected sampling methods.²³ There is also growing evidence of overall acceptability of 262 263 self-sampling methods for HPV testing among the cisgender female population, suggesting the 264 265 potential for HPV self-sampling to increase cervical cancer screening rates when compared to the standard of care pap test.²⁴ Additionally, our findings are consistent with those reported by 266 Maza et al., who also examined the acceptability of HPV self-sampling among transgender men 267 268 in El Salvador.²⁵ Both studies highlight the potential benefits of self-sampling in addressing barriers to accessing cervical cancer screening services for TGD populations. 269 270 271 Our research provides healthcare professionals with a better understanding on providing 272 medical care to the TGD population. Currently, the FDA has not approved self-collection 273 methods for use in routine HPV screening, requiring individuals AFAB to undergo specimen 274 collection by a physician in a medical clinic. Approval and implementation of self-collection 275 methods for HPV testing can increase accessibility to cervical cancer screening by removing the need for a pelvic exam, which may be a barrier for some TGD individuals who experience 276 gender dysphoria or discomfort with their genitals.²⁶ While the preference is for patients to 277

- receive in-person healthcare services with a medical professional, we acknowledge the unique barriers faced by TGD and the need for gender-affirming environments in healthcare.²⁷ We also acknowledge a profusion of internet-based services offering a variety of HPV testing; these tests are not FDA approved and are of uncertain accuracy.²⁸ It is imperative that a clinically valid, athome tests are developed and approved.
- 283

284 Additionally, while the USPSTF has moved to using gender neutral language and specify 285 anatomical features as opposed to sex, there are no transgender specific screening guidelines.^{4,29} Lack of transgender-specific guidelines and research has been shown as a 286 287 limiting factor in providing appropriate healthcare, with many providers lacking knowledge on 288 cervical cancer risk and developing a multitude of different strategies to manage care, which may not be evidence-based or appropriate for this population; potentially leading to inadequate 289 or inappropriate care and further contributing to disparities in healthcare.^{12,30} The absence of 290 clear guidelines may also affect the patient-provider relationship, with transgender individuals 291 292 potentially feeling misunderstood or unsupported by healthcare providers who are not wellversed in their specific healthcare needs.³⁰ By developing transgender-specific guidelines and 293 294 integrating self-sampling options, when approved, into cervical cancer screening protocols, healthcare providers can cater to the diverse needs of transgender patients, promote health 295 equity, and ultimately improve outcomes in this underserved population.³¹ 296

297

- 298 A strength of this study is the attention to the under-researched area of HPV and cervical cancer 299 screening among the TGD population, including nonbinary and other gender diverse individuals 300 specifically. By investigating multi-modal screening methods and focusing on a Midwestern 301 cohort rather than urban, coastal areas, the study provides valuable insights into the broader 302 TGD community's preferences and experiences with self-sampling techniques. Additionally, this study incorporated feedback from members of the TGD community who were consulted during 303 304 the study design to ensure that the study materials (consent, questionnaire, sampling 305 instructions) was comprehensive and appropriate for the population. We collected both medRxiv preprint doi: https://doi.org/10.1101/2023.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint (vquany itative: ended to the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license. 306 participants' preferences and potential barriers to screening, which can inform future 307 308 interventions and guidelines. Our study was limited in that the population sample size was 309 relatively small (although typical of studies in TGD populations), which may limit the 310 generalizability of the findings to the broader TGD population. Additionally, most participants identified as White, and thus our work may not adequately reflect the experiences and concerns 311 312 of TGD individuals from other racial and ethnic backgrounds. 313 314 Our study demonstrated the overall acceptability cervicovaginal and anal self-sampling methods
- for HPV testing and cervical cancer screening among TGD individuals AFAB, and it lays the
- 316 groundwork for future research and interventions aimed at addressing disparities in healthcare
- access and outcomes. Most participants reported a positive experience with the self-sampling
- methods, as well as an overall willingness to use these methods in the future despite any
- 319 perceived difficulty or discomfort; these results may be indicative of a potential avenue to
- increase screening uptake and reduce barriers to healthcare in this underserved population.
- 321 This study also highlights the need for tailored interventions for TGD individuals that address
- diverse preferences and experiences, and the need to develop evidence-based, transgender-
- 323 specific guidelines for HPV testing and cervical cancer screening^{25,32}. With continued research
- into the development of evidence-based and patient-centered guidelines and interventions
- tailored to the broader TGD population, we can work towards increasing accessibility and
- 326 utilization of preventative healthcare services by TGD individuals.

327 Funding

- 328 This work was supported by the University of Michigan Rogel Cancer Center (NIH grant
- 329 P30CA046592). Social media recruitment and data management was supported by the
- 330 Michigan Institute for Clinical & Health Research (CTSA grant UL1TR002240).
- 331

332 Acknowledgments

- We acknowledge our community consultants and our participants, without whom this work would not have been possible.
- 335

336 Competing interests

337 All authors declare that they have no competing interests.

References

- Cancers caused by HPV. Centers for Disease Control and Prevention. https://www.cdc.gov/hpv/parents/cancer.html. Published February 28, 2022. Accessed March 23, 2023.
- 2. Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: A review of the literature. *Human Vaccines & Immunotherapeutics*. 2018;15(1).

medRxiv ppgirt@ot086/2064551512002983951245534132; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

- Cervical cancer: Screening. Recommendation: Cervical Cancer: Screening | United States Preventive Services Taskforce. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancerscreening. Published August 21, 2018. Accessed March 23, 2023.
- Dhillon N, Oliffe JL, Kelly MT, Krist J. Bridging barriers to cervical cancer screening in transgender men: a scoping review. American journal of men's health. 2020 May;14(3):1557988320925691.
- Kattari SK, Gross EB, Harner V, et al. "Doing It On My Own Terms": Transgender and nonbinary adults' experiences with HPV self-swabbing home testing kits. *Women's Reproductive Health.* June 2022. Doi:10.1080/23293691.2022.2094737
- James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. The Report of the 2015 U.S. Transgender Survey. National Center for Transgender equality. https://transequality.org/sites/default/files/docs/usts/USTS-Full-Report-Dec17.pdf. Published December 2016. Accessed March 24, 2023.
- Peitzmeier SM, Reisner SL, Harigopal P, Potter J. Female-to-male patients have high prevalence of unsatisfactory paps compared to non-transgender females: Implications for cervical cancer screening. *Journal of General Internal Medicine*. 2014;29(5):778-784. Doi:10.1007/s11606-013-2753-1
- 8. Gatos KC. A literature review of cervical cancer screening in transgender men. Nursing for women's health. 2018 Feb 1;22(1):52-62.
- 9. Li Y, Xu C. Human papillomavirus-related cancers. *Advances in Experimental Medicine and Biology*. 2017:23-34. Doi:10.1007/978-981-10-5765-6_3
- Brown B, Poteat T, Marg L, Galea JT. Human papillomavirus-related cancer surveillance, prevention, and screening among transgender men and women: Neglected populations at high risk. *LGBT Health*. 2017;4(5):315-319. Doi:10.1089/lgbt.2016.0142
- Agénor M, Peitzmeier SM, Bernstein IM, et al. Perceptions of cervical cancer risk and screening among transmasculine individuals: Patient and provider perspectives. *Culture, Health & Sexuality*. 2016;18(10):1192-1206. Doi:10.1080/13691058.2016.1177203

- 12. Potter J, Peitzmeier SM, Bernstein I, et al. Cervical cancer screening for patients on the female-to-male spectrum: A narrative review and guide for Clinicians. Journal of General Internal Medicine. 2015;30(12). Doi:10.1007/s11606-015-3462-8
- McRee A-L, Gower AL, Reiter PL. Preventive healthcare services use among transgender young adults. *International Journal of Transgenderism*. 2018;19(4):417-423. doi:10.1080/15532739.2018.1470593

14. Centers for Disease Control and Prevention. National Health and Nutrition Examination medRxiv preprint doi: https://doi.org/10.1101/2023.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Survey (NHANES): Https://doi.org/10.1101/2023.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint Survey (NHANES): Https://doi.org/10.1101/2023.08.15.23294132; the author/funder.woo has granted medRxiv a license to display the preprint in perpetuity. 2010/manuals/HPV.pdf. Published 2009. Accessed March 24, 2023.

- 15. McIntosh RD, Andrus EC, Walling HM, Sandler CB, Goudsmit CM, Moravek MB, Stroumsa D, Kattari SK, Brouwer AF. Prevalence and determinants of cervicovaginal, oral, and anal HPV infection in a population of transgender and gender diverse people assigned female at birth. medRxiv.
- 16. Evalyn® Brush. Rovers Medical Devices. https://www.roversmedicaldevices.com/cellsampling-devices/evalyn-brush/. Published October 7, 2022. Accessed April 20, 2023.
- 17. Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: The HPV in men study. *Journal of Infectious Diseases*. 2011;204(11):1711-1722. doi:10.1093/infdis/jir637
- 18. Patel P, Bush T, Kojic EM, et al. Prevalence, incidence, and clearance of anal high-risk human papillomavirus infection among HIV-infected men in the sun study. *The Journal of Infectious Diseases*. 2017;217(6):953-963. doi:10.1093/infdis/jix607
- Eisenberg MC, Campredon LP, Brouwer AF, et al. Dynamics and determinants of HPV infection: The Michigan HPV and oropharyngeal cancer (M-hoc) study. *BMJ Open*. 2018;8(10). doi:10.1136/bmjopen-2018-021618
- 20. Gottschlich A, Rivera-Andrade A, Grajeda E, Alvarez C, Mendoza Montano C, Meza R. Acceptability of human papillomavirus self-sampling for cervical cancer screening in an indigenous community in Guatemala. *Journal of Global Oncology*. 2017;3(5):444-454. doi:10.1200/jgo.2016.005629
- 21. Zhu X, MacLaughlin KL, Fan C, et al. Awareness of HPV testing and acceptability of selfsampling for cervical cancer screening among women in Minnesota. Journal of General Internal Medicine. 2021;37(6). doi:10.1007/s11606-021-06854-x
- 22. Seay J, Ranck A, Weiss R, Salgado C, Fein L, Kobetz E. Understanding transgender men's experiences with and preferences for cervical cancer screening: A rapid assessment survey. *LGBT Health*. 2017;4(4):304-309. doi:10.1089/lgbt.2016.0143
- 23. Reisner SL, Vetters R, Leclerc M, et al. Mental health of transgender youth in care at an adolescent urban community health center: A matched retrospective cohort study. *Journal of Adolescent Health*. 2015;56(3):274-279. doi:10.1016/j.jadohealth.2014.10.264

- Johnson AH, Hill I, Beach-Ferrara J, Rogers BA, Bradford A. Common barriers to healthcare for transgender people in the U.S. Southeast. *International Journal of Transgender Health*. 2019;21(1):70-78. doi:10.1080/15532739.2019.1700203
- 25. Yeh PT, Kennedy CE, de Vuyst H, Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: A systematic review and meta-analysis. BMJ Global Health. May 2019. doi:10.1136/bmjgh-2018-001351

26. Maza M, Meléndez M, Herrera A, et al. Cervical cancer screening with human medRxiv preprint doi: https://doi.org/11.1012/2023.294132; this version posted August 16,2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. papillomavirus self-sanshubgarus author/funder. Self-sanshubgarus author/funder.

- 27. Connolly D, Hughes X, Berner A. Barriers and facilitators to cervical cancer screening among transgender men and non-binary people with a cervix: A systematic narrative review. *Preventive Medicine*. 2020;135. doi:10.1016/j.ypmed.2020.106071
- 28. Gender-affirming care for young people: A guide for healthcare providers. U.S. Department of Health and Human Services. https://opa.hhs.gov/sites/default/files/2022-03/gender-affirming-care-young-people-march-2022.pdf. Published 2022. Accessed March 24, 2023.
- 29. Underferth D. Should you get a home HPV test? MD Anderson Cancer Center. https://www.mdanderson.org/cancerwise/should-you-get-a-home-hpv-test.h00-159463212.html. Published August 18, 2021. Accessed April 15, 2023.
- 30. Caughey AB, Krist AH, Wolff TA, et al. USPSTF approach to addressing sex and gender when making recommendations for Clinical Preventive Services. *JAMA*. 2021;326(19). doi:10.1001/jama.2021.15731
- 31. Snelgrove JW, Jasudavisius AM, Rowe BW, Head EM, Bauer GR. "completely out-at-sea" with "Two-gender medicine": A qualitative analysis of physician-side barriers to providing healthcare for transgender patients. *BMC Health Services Research*. 2012;12(1). doi:10.1186/1472-6963-12-110
- Poteat T, German D, Kerrigan D. Managing uncertainty: A grounded theory of stigma in transgender health care encounters. *Social Science & Medicine*. 2013;84:22-29. doi:10.1016/j.socscimed.2013.02.019
- 33. Reisner SL, Poteat T, Keatley JA, et al. Global health burden and needs of transgender populations: A Review. *The Lancet.* 2016;388(10042):412-436. doi:10.1016/s0140-6736(16)00684-x

Table 1. Demographic characteristics of participants. (N=101)

	n	%
Age Group		
21-29	67	66.7
30-39	29	28.4
40-59	6	5.9
Race/Ethnicity		

medRxiv preprint do^{Whites:}//doi.org/10.1101/2023.08.15.23294132; thi84version po (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Multiracial It is made available under a CC-BY-NC 4.0 Integrational license.

Mataraola	U	7.0
Asian	5	4.9
Black, African American, or African	5	4.9
Gender Identity		
Nonbinary, genderfluid, agender	49	48.5
Transgender male / transmasculine / male	49	48.5
Other / Prefer not to label	2	3.0
Sexual Orientation		
Straight or heterosexual	3	2.9
Gay / Lesbian	9	8.8
Bisexual, pansexual, or omnisexual	44	43.1
Asexual or demisexual	8	7.8
Queer	37	36.3
Other / Prefer not to label	1	1.1
Highest Level of Education		
High school or less	8	7.8
Some college	27	26.5
2- or 4-year degree	46	45.1
Professional or doctorate degree	21	20.6
Marital Status		
Never married or partnered	25	11.8
Single partner, never married	12	24.5
Single partner, married	47	46.1
Multiple committed partners	11	10.9
Separated, divorced, or widowed	7	6.7
Employment status		
Student	22	21.6
Disabled and not working	10	9.8
Unemployed, not looking for work	5	4.9
Unemployed, looking for work	12	11.8
Part-time	15	14.7
Full-time	38	37.1
Yearly household income		
Less than \$10,000	17	16.8
\$10,000 - \$19,999	19	18.8

\$20,000 - \$39,999	20	19.9
\$40,000 - \$49,999	21	20.8
\$50,000 +	24	23.8
Developed Environment		
Rural	6	5.9
Suburban	49	48.0
Urban	47	46.1

medRxiv preprint do<u>Mbdireal/Msupan/do</u>.1101/2023.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Public insurance It is made available under a CC-BY-NC 4.0 International license.

Private insurance	67	66.3
None/Unsure	3	3.0

Table 2. Medical and sexual history of participants. (N=101)

	n	%
Body Mass Index (BMI), kg/m ² (N=94)		
Underweight (< 18.5 kg/m ²)	4	4.3
Normal weight (18.5-24.9 kg/m ²)	25	26.6
Overweight (25.0-29.9 kg/m ²)	31	33.0
Obese (≥ 30 kg/m²)	34	36.2

medRxiv preprint do<u>visited a/dredical10rdfessionaBviithilfstba224st3/2adh</u>is version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. No It is made available under a CC-BY-NC 4.0 International license.

No It is made available under a CO BT NO 4.0	0	7.9
Yes	93	82.1
Number of lifetime sexual partners		
< 5	34	33.7
5-10	23	22.8
> 10	44	43.6
Number of sexual partners within the past 6 months (N=99)		
0	19	19.2
1	60	60.6
2-4	17	17.2
5+	3	3.0
History of vaginal/ front hole sex (N=97)		
No	2	2.1
Yes	95	97.9
History of anal sex (N=95)		
No	38	40.0
Yes	57	60.0
History of any STI diagnosis		
No	77	76.2
Yes	24	23.8
Transitioned/transitioning from gender assigned at birth		
No	25	24.8
Yes	76	75.2
Current hormone usage for masculinization (N=57)		
No	6	10.5
Yes	51	89.5
History of pregnancy		
No	87	86.1
Yes	14	13.9
Ever had cervical Pap test or HPV test		
No	22	21.8
Yes	79	78.2
Have had prior anal Pap test		
No	95	94.1
Yes	6	5.9

Ever delayed checkups		
No	18	17.8
Yes, provider lacked knowledge on trans-specific care	6	6.0
Yes, fear of discrimination	16	15.8
Yes, to avoid dysphoria or physical discomfort	61	60.4
Have received any shots of the HPV vaccine		
No	43	42.6

medRxiv preprint doresttps://doi.org/10.1101/2023.08.15.23294132; this version posted sugust 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

										medRxiv preprint doi: https://doi.org/10.1101/2023.08 (which was not certified by peer review) is the a It is made avail			
Table 3. Prevalence and prevaler	•		•			U				hich			
uncomfortable, using the cervicova	reprir was												
for future HPV testing for cervical	not c												
ervicovaginal self-swab characteristics and outcomes. Prevalence ratios found to be statistically significant are bolded. n =													
number of individuals who respond	ded 'yes' withir	n group, N	= denom	inator for th	e given cat	egory, %	= prevale	nce of indiv	iduals	ed by			
who responded 'yes' within each g	roup (reported	l as a perc	centage),	PR = preval	ence ratio	of individu	ials who r	esponded '	yes' in	i.org/			
each group compared to the refere	ent group, and	95% CI =	95% con	fidence inte	rval for eac	h prevale	nce ratio.	Statistics w	vere	r rev It is			
calculated using Poisson regression	on with robust	error varia	ance.							iew) i mad			
										s the e ava			
	ප 드 Using the cervicovaginal self-swab was not uncomfortable HPV testing												
	n / N	%	PR	95% CI	n / N	%	PR	95% CI	n / N	294132 iunder, ndeĕa (PR	95% CI	
Overall	69 / 101	68.3	-	-	87 / 101	86.1	-	-	97 / 101	this whee h		-	
										version las gra Y-NC 4			
Demographic characteristics										nh posted August 1 anted medRxiඥa I 4.0 Internatior쯿I Ii			
Gender Identity										ed Au medF ernati			
Nonbinary, genderfluid, agender	35 / 49	71.4	1.13	0.86, 1.49	44 / 49	89.9	1.10	0.93, 1.29	48 / 49	ion 81	1.04	0.96, 1.13	
Transgender male or transmasculine	31 / 49	62.3	1.00	(Ref)	40 / 49	81.6	1.00	(Ref)	46 / 49		1.00	(Ref)	
Age Group										23. T			
21-29	47 / 66	71.2	1.00	(Ref)	57 / 66	86.4	1.00	(Ref)	63 / 66	displand 95%	1.00	(Ref)	
30-39	18 / 29	62.1	0.87	0.63, 1.20	26 / 29	89.7	1.04	0.89, 1.21	29 / 29	× بق 100005	1.05	0.99, 1.10	
40-59	4 / 6	66.7	0.94	0.52, 1.68	4 / 6	66.7	0.77	0.43, 1.37	5/6	1223. The copyright hold rise to display the preprio	0.87	0.61, 1.25	
Race/Ethnicity										lder for this preprint rint in pergetuity.			
White	56 / 83	67.5	1.00	(Ref)	73 / 83	87.9	1.00	(Ref)	82 / 83	98 get	1.00	(Ref)	
										uity.			

										medRxiv (white 85		
Multiracial / Other	5/7	71.4	1.06	0.65, 1.73	6 / 7	85.7	0.97	0.71, 1.33	6/6	85 RXIV	0.87	0.64, 1.17
Asian	4 / 6	66.7	0.99	0.55, 1.77	5/6	83.3	0.95	0.66, 1.37	6 / 7		1.01	0.99, 1.04
Black, African American, or African	4 / 5	80.0	1.19	0.75, 1.88	3/5	60.0	0.68	0.33, 1.40	3/5	10000 not coi:	0.61	0.30, 1.24
Sexual Orientation										https ertifi		
Straight / Heterosexual	1/3	33.3	0.43	0.09, 2.15	2/3	66.7	0.71	0.32, 1.60	3/3	10000	1.02	0.98, 1.07
Gay / Lesbian	6/9	66.7	0.86	0.53, 1.41	7/9	77.8	0.83	0.58, 1.19	7/9	77	0.80	0.56, 1.13
Bisexual, pansexual, or omnisexual	34 / 44	77.3	1.00	(Ref)	41 / 44	93.2	1.00	(Ref)	43 / 44	10.110	1.00	(Ref)
Asexual or demisexual	4 / 8	50.0	0.65	0.32, 1.32	6/8	75.0	0.80	0.53, 1.21	8/8		1.02	0.98, 1.07
Queer	23 / 36	63.9	0.83	0.62, 1.11	30 / 36	83.3	0.89	0.76, 1.06	35 / 36	0.1101/2023.08.1 review Os the au r dy mage atsila	0.93	0.93, 1.07
Developed environment										author/funder, who had the under a GC-B		
Rural	3/6	50.0	0.66	0.29, 1.50	5/6	83.3	0.97	0.67, 1.41	6/6	100041	1.06	0.99, 1.14
Suburban	37 / 49	75.5	1.00	(Ref)	42 / 49	85.7	1.00	(Ref)	46 / 49	a (32; th	1.00	(Ref)
Urban	29 / 46	63.0	0.83	0.64, 1.10	40 / 46	87.0	1.01	0.86, 1.19	45 / 46	B B S N N N N N N N N N N N N N N N N N	1.04	0.96, 1.13
Medical insurance	-									is version posted Augu b test granted the		
Public insurance	20 / 31	64.5	0.90	0.67, 1.22	26 / 31	83.9	0.97	0.81, 1.16	29 / 31	ed-thu	0.96	0.87, 1.07
Private insurance	48 / 67	71.6	1.00	(Ref)	58 / 67	86.6	1.00	(Ref)	65 / 67	ad Augu nation	1.00	(Ref)
										al li		
Health-related characteristics										l6, 202: icense tense		
Body Mass Index (BMI), kg/m ² (N=94)										23. The to disp		
Normal weight (18.5-24.9 kg/m ²)	19 / 25	76.0	1.00	(Ref)	22 / 25	88.0	1.00	(Ref)	25 / 25	100. ® S	1.00	(Ref)
Overweight (25.0-29.9 kg/m ²)	18 / 30	60.0	0.79	0.53, 1.15	26 / 30	86.7	0.98	0.80, 1.21	28 / 29	96.ep	0.93	0.90, 1.04
Obese (≥ 40 kg/m²)	24 / 34	70.6	0.93	0.67, 1.30	28 / 34	82.3	0.94	0.75, 1.17	32 / 34	94.rin	0.94	0.86, 1.03
Visited a medical professional within the past year										er for t t in pe		
No	5/8	62.5	0.91	0.52, 1.58	6/8	75.0	0.86	0.57, 1.29	8 / 8	100 8	1.04	1.00, 1.09
								-		tuity.		

										medRxiv (which 95.2		
Yes	64 / 93	68.8	1.00	(Ref)	81 / 93	87.1	1.00	(Ref)	89 / 93		1.00	(Ref)
Number of lifetime sexual partners										veprint doi: 97. ce 97. ce		
< 5	20 / 34	58.8	0.83	0.59, 1.17	26 / 34	76.5	0.84	0.68, 1.04	33 / 34	97. toj	1.02	0.93, 1.11
5 – 10	18 / 23	78.3	1.11	0.83, 1.48	21 / 23	91.3	1.00	0.86, 1.17	22 / 23	95. 2	1.00	0.90, 1.12
> 10	31 / 44	70.4	1.00	(Ref)	40 / 44	90.9	1.00	(Ref)	42 / 44	95. by	1.00	(Ref)
Number of sexual partners in past 6 months (N=99)										ijorg/10.1101/2023.08.15,2 <mark>y peer revi⊛v)</mark> is₄he autho It is Ɓadeœvail g ble		
0	13 / 19	68.4	1.11	0.77, 1.60	15 / 19	78.9	0.93	0.72, 1.20	19 / 19	is <mark>Xie</mark> 1099.	1.05	0.99, 1.11
1	37 / 60	61.7	1.00	(Ref)	51 / 60	85.0	1.00	(Ref)	57 / 60	listh ogav	1.00	(Ref)
2-4	14 / 17	82.3	1.33	0.99, 1.80	16 / 17	94.1	1.11	0.94, 1.30	16 / 17	08.15 Vail a bl	0.99	0.87, 1.13
History of vaginal/ front hole sex (N=99)										5.23294132; this ve thor/funder, whe ha ble under a CCABY-		
No	1 / 2	50.0	0.72	0.18, 2.90	0/2	0	-	-	0/2	4132 nder, 1 er a (-	-
Yes	66 / 97	69.5	1.00	(Ref)	85 / 95	89.5	1.00	(Ref)	93 / 95	CC AB	1.00	(Ref)
History of any STI diagnosis										version posted Aw has granted medFo Y-NC 4. Ontermatic		
No	54 / 77	70.1	1.00	(Ref)	67 / 77	87.0	1.00	(Ref)	75 / 77	anted 9 <mark>00</mark>	1.00	(Ref)
Yes	15 / 24	62.5	0.89	0.63, 1.25	20 / 24	83.3	0.96	0.78, 1.17	22 / 24	ternat	0.94	0.83, 1.07
Transitioned/transitioning from assigned gender at birth										wgust 16, 2023. The Rxiv a license todisp ttonal licen뺧 . 영		
No	18 / 25	72.0	1.07	0.80, 1.43	23 / 25	92.0	1.09	0.94, 1.27	24 / 25	ense 9	1.00	0.91, 1.10
Yes	51 / 76	67.1	1.00	(Ref)	64 / 76	84.2	1.00	(Ref)	73 / 76	todis 96.dis	1.00	(Ref)
Current hormone usage for masculinization (N=57)										te copyright holder fo splay the pr∰print∔n 10. 96 10. 96		
No	4 / 6	66.7	1.06	0.58, 1.94	5/6	83.3	0.97	0.66, 1.40	6/6	10.000 pr	1.04	0.98, 1.10
Yes	32 / 51	62.7	1.00	(Ref)	44 / 51	86.3	1.00	(Ref)	49 / 51	96.1n 96.1n	1.00	(Ref)
History of pregnancy										tr this berpe		
										dr this preprint berpetuity.		

										medRxiv (white 95.4		
No	57 / 87	65.5	1.00	(Ref)	74 / 87	85.1	1.00	(Ref)	83 / 87	95.4	1.00	(Ref)
Yes	12 / 14	85.7	1.31	1.01, 1.70	13 / 14	92.9	1.09	0.92, 1.29	14 / 14	100 as	1.05	1.00, 1.20
Ever had cervical Pap test or HPV test										not co		
No	17 / 22	77.3	1.17	0.89, 1.55	19 / 22	86.4	1.00	0.83, 1.21	21 / 22	95.4	0.99	0.90, 1.20
Yes	52 / 79	65.8	1.00	(Ref)	68 / 79	86.1	1.00	(Ref)	76 / 79	96.20	1.00	(Ref)
Ever delayed checkups										org/10. peer re It		
No	16 / 18	88.9	1.00	(Ref)	16 / 18	88.9	1.00	(Ref)	16 / 16	N.110	1.00	(Ref)
Yes, provider lacked knowledge on trans-specific care	5/6	83.3	0.94	0.63, 1.39	5/6	83.3	0.94	0.63, 1.39	6/6	0.1101/2023.08.15.23294 rewiewUs the author/turc Itos mage available wide	1.12	0.95, 1.32
Yes, fear of discrimination	9/16	56.2	0.63	0.40, 1.00	14 / 16	87.5	0.98	0.77, 1.26	16 / 16	28.15 ail@uth	1.12	0.95, 1.32
Yes, to avoid dysphoria or physical discomfort	39 / 61	63.9	0.72	0.56, 0.92	52 / 61	85.2	0.96	0.79, 1.16	59 / 61	e unid 99d	1.09	0.92, 1.29
Have received any shots of the HPV vaccine										4132; der, v er a C		
None	29 / 43	67.4	0.98	0.75, 1.28	35 / 43	81.4	0.91	0.77, 1.07	40 / 43	Cranthis v	0.95	0.87, 1.03
Yes	40 / 58	69.0	1.00	(Ref)	52 / 58	89.7	1.00	(Ref)	57 / 58	94132; this version pos Irlder, whe has granted der a CC 87-NS 4.0 h	1.00	(Ref)
										n pos: 4.0 In		
Cervicovaginal HPV self-swab characteristics	-									ted / terna		
Using the cervicovaginal swab was not difficult										August Rxiv a tional I		
No	2/14	14.3	0.18	0.05, 0.67	-	-	-	-	10 / 14	16, 2023.	0.71	0.51, 0.99
Yes	67 / 87	77.0	1.00	(Ref)	-	-	-	-	87 / 87	100 0 23	1.00	(Ref)
Using the cervicovaginal swab was not uncomfortable										. The copyrigh o display the p 9		
No	-	-	-	-	20 / 32	62.5	0.64	0.49, 0.84	29 / 32	90.00 p	0.92	0.82, 1.03
Yes	-	-	-	-	67 / 69	97.1	1.00	(Ref)	68 / 69	prepyrir 98. 98	1.00	(Ref)
Preferred method of screening for cervicovaginal cancer										der for this rt in perp		
										nis preprint petuity.		

										medl (v		
HPV self-test at home	52 / 69	75.4	1.00	(Ref)	64 / 64	92.8	1.00	(Ref)	68 / 69	98.8 <mark>h</mark> 98.8	1.00	(Ref)
HPV test in clinic collected by medical professional	4 / 7	57.1	0.76	0.39, 1.46	6 / 7	85.7	0.92	0.68, 1.26	7/7	100.9 no	1.01	0.99, 1.04
Pap test in clinic	5 / 12	41.7	0.55	0.28, 1.09	9/12	75.0	0.81	0.58, 1.13	10 / 12	83.8 1 ht	0.85	0.65, 1.09
No preference	8 / 13	61.5	0.82	0.52, 1.28	8/13	61.5	0.66	0.43, 1.02	12 / 13	92. 92	0.94	0.80, 1.10

toi.org/10.1101/2023.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint **by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Table 4. Prevalence and prevalence ratios of participant perceptions that using the anal self-swab was not uncomfortable, using the anal self-swab was not difficult, and being willing to use the anal self-swab again for future HPV testing for anal cancer by participant demographics, mediate characteristics, and cross comparisons to the anal self-swab characteristics and outcomes. Prevalence ratios found to be statistically significant are bolded. n = number of individuals who responded 'yes' within group, N = denominator within the given category, % = prevalence of individuals who responded 'yes' within each group (reported as a percentage), PR = prevalence ratio of individuals who responded 'yes' in each group compared to the referent group, and 95% CI = 95% confidence interval for each prevalence ratio. Statistics were calculated using Poisson regression with robust error variance.

	Using the	anal self-swab	was not unc	omfortable	Using	the anal self-s	wab was not	difficult	لله نة يُن ع ٢٠ Willing to use a frameself-swab for future anal HPV المتعادية المعادي المعادية المعادة المعادة المعادية المعادية المعادية المعادية المعادية المعادية المعادة المعادة المعادة المعادة المعادة المعادة المعادية المعادية المعادية المعادية المعادة المعادي المعادي المعادي المعادي المعاد المعاد المعادي المعادي المما مع معاد مع معادي معمام مع معمام معادي معادي مع معادي معمام معال				
	n	%	PR	95% CI	n	%	PR	95% CI	n	ō ⊆ (ō	PR	95% CI	
Overall	48 / 101	47.5	-	-	71 / 101	70.2	-	-	90 / 101	4132 Ider, erga (-	-	
										C-E			
Demographic characteristics										versio has gr Y-NC			
Gender Identity										n pos anted 4.0 In			
Nonbinary, genderfluid, agender	20 / 49	40.8	0.77	0.50, 1.18	33 / 49	67.3	0.94	0.72, 1.22	44 / 49	n posted August 16, 2023. ranted metaRx@ a license to 4.0 International license &	1.02	0.89, 1.18	
Transgender male or transmasculine	26 / 49	53.1	1.00	(Ref)	35 / 49	71.4	1.00	(Ref)	43 / 49	ional a	1.00	(Ref)	
Age Group										16, 20 licens icens			
21-29	35 / 66	53.0	1.00	(Ref)	52 / 66	78.8	1.00	(Ref)	59 / 66	e se 202 89-4	1.00	(Ref)	
30-39	9 / 29	31.0	0.58	0.32, 1.05	15 / 29	51.7	0.66	0.45, 0.95	25 / 29	tist 860a	0.96	0.81, 1.14	
40-59	4 / 6	66.7	1.26	0.68, 2.31	4 / 6	66.7	0.85	0.47, 1.51	6/6	The copyrig o display the 80 100 100	1.12	1.03, 1.22	
Race/Ethnicity										nt holi prepri			
White	39 / 83	47.0	1.00	(Ref)	58 / 83	69.9	1.00	(Ref)	77 / 83	92m r	1.00	(Ref)	
Multiracial	4 / 7	57.1	1.22	0.61, 2.40	4 / 7	57.1	0.82	0.42, 1.58	5/7	715e	0.82	0.42, 1.58	
										nt holder for this preprint preprint였 petpetuity. ~			

										med		
Asian	3/6	50.0	1.06	0.46, 2.45	6/6	100.0	1.43	1.24, 1.65	6/6	medRxiy preprint doi: http: (whigh was not certify 10h vas not certify 10d	1.43	1.24, 1.65
Black, African American, or African	2/5	40.0	0.85	0.28, 2.55	3/5	60.0	0.86	0.41, 1.78	2/5		0.86	0.41, 1.78
Sexual Orientation										not o		
Straight or heterosexual	2/3	66.7	1.83	0.75, 4.47	2/3	66.7	0.98	0.43, 2.23	3/3	1000	1.13	1.01, 1.25
Homosexual	6 / 9	66.7	1.83	1.00, 3.36	7/9	77.8	1.14	0.76, 1.71	7/9	ied 90. 7799	0.88	0.61, 1.26
Bisexual, pansexual, or omnisexual	16 / 44	36.4	1.00	(Ref)	30 / 44	68.2	1.00	(Ref)	39 / 44	888 F	1.00	(Ref)
Asexual or demisexual	4 / 8	50.0	1.37	0.62, 3.05	4 / 8	50.0	0.73	0.36, 1.51	8/8		1.13	1.00, 1.26
Queer	19 / 36	52.8	1.45	0.88, 4.06	27 / 36	75.0	1.10	1.20, 1.79	32 / 36	101/202 iewois made	1.00	0.86, 1.17
Developed environment					-					3.08. the a availa		
Rural	4 / 6	66.7	1.42	0.75, 2.69	6/6	100.0	1.53	1.25, 1.88	6/6	1523 utlterr 距距 u	1.19	1.06, 1.35
Suburban	23 / 49	46.9	1.00	(Ref)	32 / 49	65.3	1.00	(Ref)	41 / 49	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1.00	(Ref)
Urban	21 / 46	45.7	0.97	0.63, 1.50	33 / 46	71.7	1.20	0.84, 1.44	43 / 46	s the author/functer, Who s the author/functer, Who e availab@ under a CC-	1.12	0.97, 1.29
Medical insurance										ns version posted no has granted The BY-NC & 0 Intern		
Public insurance	9 / 31	29.0	0.51	0.28, 0.92	23 / 31	74.2	1.06	0.82, 1.37	26 / 31	grant p	0.92	0.78, 1.09
Private insurance	38 / 67	56.7	1.00	(Ref)	47 / 67	29.8	1.00	(Ref)	61 / 67		1.00	(Ref)
										불성도		
Health-related characteristics										ligust 16 Xiv a lib		
Body Mass Index (BMI), kg/m ² (N=100)										l6, 2023. ibense to dense		
Normal weight (18.5-24.9 kg/m ²)	12 / 25	48.0	1.00	(Ref)	18 / 25	72.0	1.00	(Ref)	21 / 25	to 93. 8495 8495	1.00	(Ref)
Overweight (25.0-29.9 kg/m ²)	14 / 30	46.7	0.97	0.54, 1.73	21 / 30	70.0	0.97	0.68, 1.38	27 / 29	plate 93⊀t	1.11	0.90, 1.36
Obese (≥ 30 kg/m²)	16 / 34	47.1	0.98	0.56, 1.72	22 / 34	64.7	0.90	0.63, 1.29	31 / 34	. The copyright h ວ ສູ່ຊຸຣplay, the pre	1.09	0.88, 1.34
Visited a medical professional within the past year										holder for this preprint eprint in perpetuity.		
No	6 / 8	75.0	1.66	1.05, 2.63	5/8	62.5	0.88	0.51, 1.53	8 / 8	л 10080-т 1008-т	1.13	1.05, 1.22
										his pre		
										eprint ty.		

										med		
Yes	42 / 93	45.2	1.00	(Ref)	66 / 93	71.0	1.00	(Ref)	82 / 93	medRxiv pr (whiteh)	1.00	(Ref)
Number of lifetime sexual partners										reprint doi: h was noi cer		
< 5	17 / 34	50.0	1.10	0.69, 1.75	25 / 34	73.5	0.98	0.75, 1.28	29 / 34	85 ³⁰	0.89	0.77, 1.04
5 – 10	11 / 23	47.8	1.05	0.62, 1.80	13 / 23	56.5	0.75	0.51, 1.12	19 / 23	82 <mark>.6</mark>	0.86	0.71, 1.05
> 10	20 / 44	45.5	1.00	(Ref)	33 / 44	75.0	1.00	(Ref)	42 / 44	95 9	1.00	(Ref)
Number of partners in past 6 months (N=99)										org/1 peer		
0	10 / 19	52.6	1.13	0.68, 1.87	12 / 19	63.2	0.86	0.59, 1.25	15 / 19		0.85	0.66, 1.08
1	28 / 60	46.7	1.00	(Ref)	44 / 60	73.3	1.00	(Ref)	56 / 60	nade	1.00	(Ref)
2-4	8 / 17	47.1	1.01	0.57, 1.79	12 / 17	70.6	0.96	0.68, 1.36	14 / 17	availa	0.88	0.70, 1.11
History of any STI diagnosis										org/10.1101/2023.08.15.23294132: th peer regiew/13 th@author/funder, %h It% made available under a GC		
No	34 / 77	44.2	1.00	(Ref)	53 / 77	68.8	1.00	(Ref)	67 / 77	2941: funder nder	1.00	(Ref)
Yes	14 / 24	58.3	1.32	0.87, 2.01	18 / 24	75.0	1.09	0.83, 1.43	23 / 28	a 600-	1.10	0.98, 1.24
Transitioned/transitioning from assigned gender at birth										his version posted Aug no has granted media S-BY-NC 4. Wintermatic		
No	7 / 25	28.0	0.52	0.27, 1.01	14 / 25	56.0	0.75	0.51, 1.08	23 / 25	t opension	1.04	0.90, 1.20
Yes	41 / 76	54.0	1.00	(Ref)	57 / 76	75.0	1.00	(Ref)	67 / 76	med Ar	1.00	(Ref)
Current hormone usage for masculinization (N=57)										wgust 16_2023. T Rxiv a liœnsetto Itonal liceີກຣe ອິ		
No	3/6	50.0	0.80	0.35, 1.82	5/6	83.3	1.06	0.72, 1.56	6 / 6	16_20 licහn සිහි	1.11	1.01, 1.21
Yes	32 / 51	62.8	1.00	(Ref)	40 / 51	78.4	1.00	(Ref)	46 / 51	6 Se 22 90-2.	1.00	(Ref)
History of anal sex (N=95)										lhe co displa		
No	18 / 38	47.4	0.96	0.63, 1.48	26 / 38	68.4	0.97	0.74, 1.28	33 / 38		0.95	0.82, 1.10
Yes	28 / 57	49.1	1.00	(Ref)	40 / 57	70.2	1.00	(Ref)	52 / 57	The copyright hold o display (ge pr@brit 8 o	1.00	(Ref)
Ever had pap smear or HPV test for anal cancer										rint in pepetuity.		
No	48 / 95	50.5	1.00	(Ref)	67 / 95	70.5	1.00	(Ref)	87 / 95	peffee 916e	1.00	(Ref)
										prepr tuity.		
										int		

										medRxiv pr (whiteh)		
Yes	0/6	0	-	-	4 / 6	66.7	0.94	0.53, 1.69	3/6	5000 XX	0.55	0.24, 1.22
Ever delayed checkups										reprir was		
No	4 / 18	22.2	1.00	(Ref)	9/18	50.0	1.00	(Ref)	15 18	reprint doi: h was noi? cer	1.00	(Ref)
Yes, provider lacked knowledge on trans-specific care	4/6	66.7	3.00	1.07, 8.43	6/6	100.0	2.00	1.26, 1.67	5/6	83 <mark>=3</mark> =	1.00	0.66, 1.51
Yes, fear of discrimination	10 / 16	62.5	2.81	1.09, 7.23	13 / 16	81.2	1.62	0.97, 2.73	16 / 16	10000	1.20	0.98, 1.47
Yes, to avoid dysphoria or physical discomfort	30 / 61	49.2	2.21	0.90, 5.45	43 / 61	70.5	1.41	0.86, 2.30	54 / 61	88 88 88 17 10.1	1.06	0.85, 1.33
Have received any shots of the HPV vaccine										.1101/2023.08.15.2 eview) is the author t is madeavailable		
No	18 / 43	41.9	0.81	0.53, 1.24	26 / 43	60.5	0.78	0.59, 1.03	36 / 43	decay	0.90	0.78, 1.04
Yes	30 / 58	51.7	1.00	(Ref)	45 / 58	77.6	1.00	(Ref)	54 / 58	2 08.15	1.00	(Ref)
										23294132; this version posted pr/funder, who has grantectine e under a CC-BY-NC K.0 Intern		
Anal HPV self-swab characteristics										f a CC-		
Using the anal swab was not difficult										s ver b has BY-N		
No	4 / 30	13.3	0.21	0.08, 0.54	-	-	-	-	21 / 30	Gran p	0.72	0.57, 0.91
Yes	44 / 71	62.0	1.00	(Ref)	-	-	-	-	69 / 71		1.00	(Ref)
Using the anal swab was not uncomfortable										ad Aug ation		
No	-	-	-	-	27 / 53	50.9	0.55	0.42, 1.73	42 / 53	v afiio Nalie	0.79	0.69, 0.91
Yes	-	-	-	-	44 / 48	91.7	1.00	(Ref)	48 / 48	d August 16, 2023 edRxiv anicen⊛e mationalikcen⊛ .	1.00	(Ref)
Preferred method of screening for anal cancer										3. The		
HPV self-test at home	41 / 67	61.2	1.00	(Ref)	57 / 67	85.1	1.00	(Ref)	65 / 67	972000	1.00	(Ref)
HPV test in clinic collected by medical professional	4 / 13	30.8	0.50	0.22, 1.16	4/13	30.8	0.36	0.16, 0.82	10 / 13	theor 76or	0.79	0.59, 1.07
Pap test in clinic	2/8	25.0	0.41	0.12, 1.38	3/8	37.5	0.44	0.18 1.08	6/8	3. The copyright holder to display the prepfint in	0.77	0.52, 1.16
No preference	1 / 13	7.7	0.13	0.02, 0.83	7/13	53.8	0.63	0.38, 1.06	9/13	t in 20er 69er	0.71	0.49, 1.03
										this preprint petuity.		
										Print		

medRxiv preprint doi: https://doi.org/10.1101/2023.08.15.23294132; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .